We are significantly undervalued once convertible notes are done. We have been impacted due to the sell pressure of dilution, not necessarily because "our shares are now worthless because there are too many"
- trailing 12 month revenue is $4.5M, with a gross margin of $2.5M
- this is expected to improve in the next release but how much we will see - revenue up 44% YoY so far, but last Q4 was our strongest quarter last year, and our gains in Q1 and Q2 (56-58%) were faster than Q3 (25%) - but gross margin % improved in Q3 - and my hope is pet meds significantly increase sales in Q4.
We will end with somewhere between 700M and 1.1B shares. I personally do not think they will raise the 900M cap to cater to the debt conversions so 900M is the likely ending point. I personally hope they pay it off around 700M if they can. I think there may possibly be some signs of this recently.
At an assumed 900M shares, we are below 2x revenue with our current price and trailing 12 month revenue.
Our gross margin % is significantly better than POTN, who has deceivingly higher revenues but but not as high of gross margin comparative to us. Their trailing 9 month rev/margin are $9.5M and $3.5M. Ours are $3.3M and $1.8M (1/3 the rev, 1/2 the margin). We have lower fixed costs but they still have higher income due to the 3.5 vs 1.8 difference in margin. They have a nearly identical o/s and a/s (560M, 1B), as well as conversion situation. (to be clear the numbers in this paragraph are 9 months, easier to compare quickly, i have ubqu readily accessible by quarter for years but not potn)
- They trade at 5.8 cents. If you give us half that based on margin difference, you can argue we should be 2.9 cents
